About Odonate Therapeutics (NASDAQ:ODT)
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It focuses on the development of tesetaxel, an orally administered chemotherapy agent for patients with advanced or metastatic breast cancer (MBC). Odonate Therapeutics, Inc. also conducting a Phase III study in MBC, which is known as CONTESSA. The company was founded in 2013 and is based in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ODT
CUSIPN/A
Phone858-731-8180
Debt
Debt-to-Equity RatioN/A
Current Ratio27.02%
Quick Ratio27.02%
Price-To-Earnings
Trailing P/E Ratio-9.44
Forward P/E Ratio-4.96
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$7.29 per share
Price / Book2.93
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees60
Outstanding Shares27,330,000
Odonate Therapeutics (NASDAQ:ODT) Frequently Asked Questions
What is Odonate Therapeutics' stock symbol?
Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."
How were Odonate Therapeutics' earnings last quarter?
Odonate Therapeutics (NASDAQ:ODT) posted its quarterly earnings results on Wednesday, February, 14th. The company reported ($0.81) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.67) by $0.14. View Odonate Therapeutics' Earnings History.
What price target have analysts set for ODT?
3 brokers have issued 12 month target prices for Odonate Therapeutics' shares. Their forecasts range from $27.00 to $40.00. On average, they expect Odonate Therapeutics' share price to reach $33.50 in the next twelve months. View Analyst Ratings for Odonate Therapeutics.
Who are some of Odonate Therapeutics' key competitors?
Some companies that are related to Odonate Therapeutics include PTC Therapeutics (PTCT), Revance Therapeutics (RVNC), Mallinckrodt (MNK), WAVE Life Sciences (WVE), Epizyme (EPZM), Intra-Cellular Therapies (ITCI), Athenex (ATNX), Retrophin (RTRX), Zai Lab (ZLAB), TG Therapeutics (TGTX), CytomX Therapeutics (CTMX), MacroGenics (MGNX), Flexion Therapeutics (FLXN), Alder BioPharmaceuticals (ALDR), Assembly Biosciences (ASMB), Biohaven Pharmaceutical (BHVN), Uniqure (QURE) and Mirati Therapeutics (MRTX).
Who are Odonate Therapeutics' key executives?
Odonate Therapeutics' management team includes the folowing people:
- Mr. Kevin C. Tang, Chairman & CEO (Age 51)
- Mr. John G. Lemkey, Chief Financial Officer (Age 37)
- Dr. Steven S. Pfeiffer Ph.D., VP of Technical Operations (Age 42)
- Ms. Nicole H. Gollaher J.D., VP of Legal Affairs (Age 49)
- Dr. Joseph P. O'Connell M.D., Chief Medical Officer (Age 64)
When did Odonate Therapeutics IPO?
(ODT) raised $150 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 5,900,000 shares at $24.00-$27.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Cowen was co-manager.
When does the company's lock-up period expire?
Odonate Therapeutics' lock-up period expires on Tuesday, June 5th. Odonate Therapeutics had issued 6,250,000 shares in its initial public offering on December 7th. The total size of the offering was $150,000,000 based on an initial share price of $24.00. After the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.
Has Odonate Therapeutics been receiving favorable news coverage?
Media coverage about ODT stock has trended somewhat positive recently, Accern reports. The research firm scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Odonate Therapeutics earned a daily sentiment score of 0.17 on Accern's scale. They also assigned press coverage about the company an impact score of 46.42 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Odonate Therapeutics?
Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Odonate Therapeutics' stock price today?
One share of ODT stock can currently be purchased for approximately $21.33.
How big of a company is Odonate Therapeutics?
Odonate Therapeutics has a market capitalization of $616.32 million. The company earns $-32,740,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis. Odonate Therapeutics employs 60 workers across the globe.
How can I contact Odonate Therapeutics?
Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]
MarketBeat Community Rating for Odonate Therapeutics (ODT)
MarketBeat's community ratings are surveys of what our community members think about Odonate Therapeutics and other stocks. Vote "Outperform" if you believe ODT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ODT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Odonate Therapeutics (NASDAQ:ODT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Odonate Therapeutics in the last 12 months. Their average twelve-month price target is $33.50, suggesting that the stock has a possible upside of 57.06%. The high price target for ODT is $40.00 and the low price target for ODT is $27.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | N/A |
| Consensus Rating Score: | 2.67 | 2.67 | 2.67 | N/A |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $33.50 | $33.50 | $33.50 | N/A |
| Price Target Upside: | 57.06% upside | 34.00% upside | 34.00% upside | N/A |
Odonate Therapeutics (NASDAQ:ODT) Consensus Price Target History
Odonate Therapeutics (NASDAQ:ODT) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 1/2/2018 | Goldman Sachs | Initiated Coverage | Neutral -> Neutral | $27.00 | Low |  |
| 1/2/2018 | Cowen | Initiated Coverage | Outperform | | Medium | |
| 1/2/2018 | Jefferies Group | Initiated Coverage | Buy -> Buy | $40.00 | Medium | |
(Data available from 4/19/2016 forward)
Odonate Therapeutics (NASDAQ:ODT) Earnings History and Estimates Chart
Odonate Therapeutics (NASDAQ:ODT) Earnings Estimates
2018 EPS Consensus Estimate: ($4.30)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2018 | 1 | ($0.86) | ($0.86) | ($0.86) |
| Q2 2018 | 1 | ($0.98) | ($0.98) | ($0.98) |
| Q3 2018 | 1 | ($1.15) | ($1.15) | ($1.15) |
| Q4 2018 | 1 | ($1.31) | ($1.31) | ($1.31) |
Odonate Therapeutics (NASDAQ ODT) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 2/14/2018 | Q4 2017 | ($0.67) | ($0.81) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Odonate Therapeutics (NASDAQ:ODT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Odonate Therapeutics (NASDAQ ODT) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 78.92%
Odonate Therapeutics (NASDAQ ODT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/26/2018 | Boxer Capital, Llc | Director | Buy | 100,000 | $22.73 | $2,273,000.00 | | |
| 3/1/2018 | Kevin C Tang | CEO | Buy | 14,050 | $27.42 | $385,251.00 | | |
| 2/27/2018 | Kevin C Tang | CEO | Buy | 28,612 | $27.42 | $784,541.04 | | |
| 2/22/2018 | Kevin C Tang | CEO | Buy | 39,083 | $27.17 | $1,061,885.11 | | |
| 2/16/2018 | Kevin C Tang | CEO | Buy | 128,255 | $22.47 | $2,881,889.85 | | |
| 12/12/2017 | Jeff L Vacirca | Director | Buy | 1,000 | $23.30 | $23,300.00 | | |
| 12/7/2017 | Kevin C Tang | CEO | Buy | 1,291,666 | $24.00 | $30,999,984.00 | | |
| 12/6/2017 | Boxer Capital, Llc | Director | Buy | 416,666 | $24.00 | $9,999,984.00 | | |
(Data available from 1/1/2013 forward)
Odonate Therapeutics (NASDAQ ODT) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Odonate Therapeutics (ODT) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - April 18 at 10:04 AM |
| Head to Head Review: Neos Therapeutics (NEOS) and Odonate Therapeutics (ODT)
www.americanbankingnews.com - April 13 at 9:05 AM |
| Analysts Expect Odonate Therapeutics (ODT) Will Announce Earnings of -$0.86 Per Share
www.americanbankingnews.com - April 10 at 7:21 PM |
| Odonate Therapeutics (ODT) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - April 8 at 7:28 AM |
| Jefferies Group Initiates Coverage on Odonate Therapeutics (ODT)
www.americanbankingnews.com - March 31 at 12:49 PM |
| Boxer Capital, Llc Acquires 100,000 Shares of Odonate Therapeutics (ODT) Stock
www.americanbankingnews.com - March 26 at 10:10 PM |
| Analysts Anticipate Odonate Therapeutics (ODT) to Announce ($0.86) Earnings Per Share
www.americanbankingnews.com - March 24 at 12:26 PM |
| Analysts Anticipate Odonate Therapeutics (ODT) to Announce ($0.86) EPS
www.americanbankingnews.com - March 19 at 1:34 PM |
| Zacks: Brokerages Set $40.00 Target Price for Odonate Therapeutics Inc (ODT)
www.americanbankingnews.com - March 11 at 5:28 PM |
| Zacks Investment Research Downgrades Odonate Therapeutics (ODT) to Sell
www.americanbankingnews.com - March 11 at 1:48 PM |
| Odonate Therapeutics Inc (ODT) Given $40.00 Consensus Price Target by Brokerages
www.americanbankingnews.com - March 8 at 5:25 PM |
| Analysts Anticipate Odonate Therapeutics Inc (ODT) to Post -$0.86 EPS
www.americanbankingnews.com - March 7 at 3:18 PM |
 | Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Bought $385,251 of Shares
finance.yahoo.com - March 3 at 9:22 AM |
| Odonate Therapeutics Inc (ODT) CEO Buys $385,251.00 in Stock
www.americanbankingnews.com - March 2 at 6:40 PM |
| Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Bought $784,541 of Shares
finance.yahoo.com - February 28 at 9:21 AM |
| Kevin C. Tang Purchases 28,612 Shares of Odonate Therapeutics Inc (ODT) Stock
www.americanbankingnews.com - February 27 at 6:32 PM |
| Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Bought $1.1 million of Shares
finance.yahoo.com - February 23 at 9:20 AM |
| Kevin C. Tang Purchases 39,083 Shares of Odonate Therapeutics Inc (ODT) Stock
www.americanbankingnews.com - February 22 at 9:20 PM |
| Odonate Therapeutics Inc (ODT) CEO Kevin C. Tang Buys 128,255 Shares
www.americanbankingnews.com - February 16 at 9:10 PM |
| Jefferies Group Brokers Cut Earnings Estimates for Odonate Therapeutics Inc (ODT)
www.americanbankingnews.com - February 16 at 7:56 AM |
| Odonate Therapeutics (ODT) Issues Quarterly Earnings Results
www.americanbankingnews.com - February 15 at 11:52 PM |
| Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2017
finance.yahoo.com - February 14 at 9:12 AM |
| Odonate Therapeutics LLC's (ODT) Quiet Period Set To End on January 16th
www.americanbankingnews.com - January 9 at 1:22 AM |
| Odonate Therapeutics LLC to Post FY2017 Earnings of ($1.83) Per Share, Jefferies Group Forecasts (ODT)
www.americanbankingnews.com - January 4 at 6:34 AM |
| Odonate Therapeutics (ODT) Now Covered by Goldman Sachs Group
www.americanbankingnews.com - January 2 at 10:18 AM |
| Odonate Therapeutics (ODT) Coverage Initiated at Cowen
www.americanbankingnews.com - January 2 at 8:04 AM |
| Jeff L. Vacirca Purchases 1,000 Shares of Odonate Therapeutics LLC (ODT) Stock
www.americanbankingnews.com - December 14 at 9:38 PM |
| Odonate Therapeutics LLC (ODT) Director Boxer Capital, Llc Purchases 416,666 Shares
www.americanbankingnews.com - December 8 at 8:28 PM |
| Insider Buying: Odonate Therapeutics LLC (ODT) CEO Acquires 1,291,666 Shares of Stock
www.americanbankingnews.com - December 8 at 5:30 PM |
Odonate Therapeutics (NASDAQ:ODT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Odonate Therapeutics (NASDAQ ODT) Stock Chart for Thursday, April, 19, 2018
Loading chart…
